Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in the United States
Open Access
- 28 April 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (2) , 342-351
Abstract
Background: Antibiotic-nonsusceptible invasive pneumococcal disease (NS-IPD) incidence declined dramatically in the United States after introduction of pneumococcal conjugate vaccines (PCVs) into the infant immunization schedule (7-valent PCV7 in 2000, replaced by the 13-valent PCV13 in 2010). We evaluated the long-term impact of PCVs on NS-IPD. Methods: We identified IPD cases through the Centers for Disease Control Active Bacterial Core surveillance during 1998–2018. Isolates intermediate or resistant to ≥1 antibiotic class were classified as nonsusceptible. We calculated annual rates of IPD (cases per 100 000 persons). Results: From 1998 through 2018, NS-IPD incidence decreased from 43.9 to 3.2 among children <5 years and from 19.8 to 9.4 among adults ≥65 years. Incidence of vaccine-type NS-IPD decreased in all age groups, whereas incidence of nonvaccine type (NVT) NS-IPD increased in all age groups; the greatest absolute increase in NVT NS-IPD occurred among adults ≥65 years (2.3 to 7.2). During 2014–2018, NVTs 35B, 33F, 22F, and 15A were the most common NS-IPD serotypes. Conclusions: Nonsusceptible IPD incidence decreased after PCV7 and PCV13 introduction in the United States. However, recent increases in NVT NS-IPD, most pronounced among older adults, have been observed. New higher valency PCVs containing the most common nonsusceptible serotypes, including 22F and 33F, could help further reduce NS-IPD.Keywords
Funding Information
- Centers for Disease Control and Prevention
- Emerging Infections Program
This publication has 32 references indexed in Scilit:
- Novel Pneumococcal Serotypes 6C and 6D: Anomaly or HarbingerClinical Infectious Diseases, 2012
- Prevention of Antibiotic-Nonsusceptible Streptococcus pneumoniae With Conjugate VaccinesThe Journal of Infectious Diseases, 2011
- Executive Summary: The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Outpatient Antibiotic Prescribing and Nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003Clinical Infectious Diseases, 2011
- Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate VaccineThe Journal of Infectious Diseases, 2010
- Differential Effects of Pneumococcal Vaccines against Serotypes 6A and 6CThe Journal of Infectious Diseases, 2008
- Population Snapshot of EmergentStreptococcus pneumoniaeSerotype 19A in the United States, 2005The Journal of Infectious Diseases, 2008
- Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-ResistantStreptococcus pneumoniaeNew England Journal of Medicine, 2006
- The Impact of Penicillin Resistance on Short-Term Mortality in Hospitalized Adults with Pneumococcal Pneumonia: A Systematic Review and Meta-AnalysisClinical Infectious Diseases, 2006
- Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate VaccineNew England Journal of Medicine, 2003